Insufficient blood perfusion is now recognized as a “common denominator” underlying many deadly and debilitating conditions, including diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, and numerous other disorders.
Zhittya currently has eight active drug development programs to treat vascular disorders in the brain, feet and heart as well as many others throughout the body.
As we oversee the clinical development of different formulations of FGF-1 for unique medical indications we will work with marketing partners around the world.
Parkinson’s Disease: Zhittya Regenerative Medicine’s research has indicated that Parkinson’s might be a result of reduced blood flow to the brain, especially to the nerves that produce dopamine. ZRM plans to perform clinical trials to see if Parkinson’s patients will improve from administering FGF-1 to the brain.
To Learn More, Please Watch Our Video